Search results
Results from the WOW.Com Content Network
Ceftriaxone, sold under the brand name Rocephin, is a third-generation cephalosporin antibiotic used for the treatment of a number of bacterial infections. [4] These include middle ear infections, endocarditis, meningitis, pneumonia, bone and joint infections, intra-abdominal infections, skin infections, urinary tract infections, gonorrhea, and pelvic inflammatory disease. [4]
The first line treatments recommended by the U.S. Centers for Disease Control and Prevention are one of four options: azithromycin one gram orally in a single dose, ceftriaxone 250 mg intramuscularly in a single dose, ciprofloxacin 500 mg orally two times a day for three days, or erythromycin base 500 mg orally three times a day for seven days.
The Prescribing Information follows one of two formats: "physician labeling rule" format or "old" (non-PLR) format. For "old" format labeling a "product title" may be listed first and may include the proprietary name (if any), the nonproprietary name, dosage form(s), and other information about the product.
For ceftriaxone, the color of solutions can range from light yellow to amber, depending on the length of storage, concentration, and diluent used. [ 30 ] [ 31 ] A study found that meropenem concentrations dropped to 90% of the initial concentration at 7.4 hours at 22°C and 5.7 hours at 33°C, indicating degradation over time.
Created Date: 8/30/2012 4:52:52 PM
Since August 2012, the third-generation cephalosporin, ceftriaxone, is the only recommended treatment for gonorrhea in the United States (in addition to azithromycin or doxycycline for concurrent Chlamydia treatment). Cefixime is no longer recommended as a first-line treatment due to evidence of decreasing susceptibility. [30] Ceftriaxone ...
Cephalosporins are a broad class of bactericidal antibiotics that include the β-lactam ring and share a structural similarity and mechanism of action with other β-lactam antibiotics (e.g. penicillins, carbapenems and monobactams). [1]
Clinical trials sponsored by Novo Nordisk found that participants with obesity or overweight (but without type 2 diabetes) lost 15.2 percent of their body weight after 104 weeks of 2.4 milligrams ...